Albert Bourla, Pfizer CEO (AP Photo/Markus Schreiber)
May 2, 2023 01:45 PM EDT
Pharma

With Covid sales de­clin­ing, Pfiz­er ze­roes in on M&A and on­col­o­gy

Tyler Patchen

News Reporter

Pfiz­er’s first-quar­ter rev­enue tum­bled, as ex­pect­ed, due to dwin­dling sales of its Covid-19 prod­ucts, yet ex­ec­u­tives sought to re­in­force the com­pa­ny’s re­newed fo­cus on can­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times